Vaxcyte, Inc. (PCVX) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
PCVX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
PCVX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export PCVX earnings history in CSV or JSON format
Free sign-in required to download data
Vaxcyte, Inc. (PCVX) Earnings Overview
As of May 8, 2026, Vaxcyte, Inc. (PCVX) reported trailing twelve-month net income of -$947M, reflecting -48.2% year-over-year growth. The company earned $-6.78 per diluted share over the past four quarters.
Looking at the long-term picture, PCVX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$17M in fiscal 2017.
Vaxcyte, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PFE ($7.49B net income, 12.4% margin), MRK ($18.25B net income, 28.1% margin), GSK ($6.40B net income, 17.5% margin), PCVX has comparable earnings metrics. Compare PCVX vs PFE →
PCVX Earnings vs Peers
Earnings metrics vs comparable public companies
PCVX Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$767M | -65.2% | -$924M | $-5.63 | - | - |
| 2024 | -$464M | -15.3% | -$570M | $-3.80 | - | - |
| 2023 | -$402M | -80.0% | -$468M | $-4.14 | - | - |
| 2022 | -$223M | -123.3% | -$232M | $-3.44 | - | - |
| 2021 | -$100M | -12.2% | -$104M | $-1.93 | - | - |
| 2020 | -$89M | -77.5% | -$90M | $-2.97 | - | - |
| 2019 | -$50M | -70.5% | -$54M | $-14.10 | - | - |
| 2018 | -$29M | -71.0% | -$36M | $-8.12 | - | - |
| 2017 | -$17M | - | -$18M | $-4.83 | - | - |
See PCVX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PCVX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PCVX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPCVX — Frequently Asked Questions
Quick answers to the most common questions about buying PCVX stock.
Is PCVX growing earnings?
PCVX EPS fell to $-6.78, with earnings declining -48.2%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-947M.
What are PCVX's profit margins?
Vaxcyte, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are PCVX's earnings?
PCVX earnings data spans 2017-2025. The declining earnings trend is -48.2% YoY. Historical data enables comparison across business cycles.